heart attack – pharmaceutical daily

August 27, 2017 Off

Novartis’s new drug reduces cardiovascular risk

Novartis has revealed primary data from CANTOS, a Phase III study evaluating quarterly injections of ACZ885 (canakinumab) in people with a prior heart attack and inflammatory atherosclerosis as measured by high-sensitivity C-reactive protein (hsCRP) levels of >=2mg/L, a known marker of inflammation.

June 22, 2017 Off

Novartis’s large heart attack realted study meets endpoints

By Dino Mustafić

Novartis’s Phase III Cantos study of ACZ885 (canakinumab), one of the largest in the company’s history, combined with standard of care in people with a prior heart attack and inflammatory atherosclerosis has met the primary endpoint.

March 13, 2017 Off

TiGenix’s hearth attack study confirms the long term safety

By Dino Mustafić

TiGenix has found in its acute hearth attack study that allogenic cardiac stem cells can be transplanted safely through the coronary tree.